echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Takeda's first COVID-19 vaccine approved in Japan for primary and booster immunization

    Takeda's first COVID-19 vaccine approved in Japan for primary and booster immunization

    • Last Update: 2022-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    April 23, 2022 / eMedClub News / -- On April 19, 2022, Takeda announced that it has obtained a license from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market Nuvaxovid
    .

    Nuvaxovid is a novel recombinant protein-based COVID-19 vaccine for primary and booster immunizations in people 18 years of age and older
    .

    Nuvaxovid (called NVX-CoV2373 outside Japan and TAK-019 inside Japan) is the first protein vaccine approved for use in Japan
    .

    NVX-CoV2373 was developed by Novavax and was first approved for marketing in the EU in December 2021
    .

    In August 2020, Takeda introduced its development, production and commercialization rights in Japan
    .

    According to the press release, Takeda expects to produce more than 250 million doses of the COVID-19 vaccine annually
    .

    The vaccine is an antigen derived from the new coronavirus spike protein and is used in conjunction with Matrix-M adjuvant (saponin-based adjuvant) to enhance the immune response and the production of neutralizing antibodies in the human body
    .

    NVX-CoV2373 has a total of two doses, with a 21-day interval between vaccinations.
    It can be stored in an environment of 2-8 degrees Celsius, which is easier to store and transport, and is beneficial to low- and middle-income countries
    .

    About Matrix-M™ Adjuvant Novavax's patented saponin Matrix-M™ adjuvant has shown potent and well-tolerated effects by stimulating antigen-presenting cells to enter the injection site and enhancing antigen presentation in regional lymph nodes, enhancing immune responses
    .

    About the TAK-019 Clinical Trial This placebo-controlled Phase 1/2 study in Japan evaluated the safety and immunogenicity of two TAK-019 vaccinations administered 21 days apart
    .

    On February 24, 2021, the first of 200 subjects aged 20 and older was dosed in Japan, each assigned to receive either placebo or 0.
    5 ml doses of TAK- 019
    .

    Subjects were followed for 12 months after the second dose of investigational product
    .

    About NVX-CoV2373 Phase 3 Trials NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials
    .

    PREVENT-19, a trial conducted in the United States and Mexico, enrolled nearly 30,000 participants aged 18 years and older, with an overall efficacy rate of 90.
    4%
    .

    It was designed as a 2:1 randomized, placebo-controlled, observer-blind study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373
    .

    The primary endpoint of PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 and after the second dose at baseline in seronegative (for SARS-CoV-2) adult subjects Onset for at least 7 days
    .

    Statistical success criteria included a lower limit of 95% CI > 30%
    .

    The secondary endpoint was prevention of PCR-confirmed, symptomatic moderate or severe COVID-19
    .

    Volunteers who had not previously been infected with SARS-CoV-2 were assessed at least seven days after the second study vaccination
    .

    In both studies, it was generally well tolerated and elicited a strong antibody response after the second dose
    .

    The full results of the trial were published in the New England Journal of Medicine (NEJM)
    .

    A trial conducted in the United Kingdom, with 14,039 subjects aged 18 years and over, was designed as a randomized, placebo-controlled, observer-blinded study with an overall efficacy of 89.
    7%
    .

    The primary endpoint is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 and seronegative (for SARS-CoV-2) adult subjects at baseline for at least 7 days after the second study vaccination day sickness
    .

    The full results of the trial are published in NEJM
    .

    About Novavax Novavax, Inc.
    is a biotechnology company that contributes to the improvement of global health by discovering, developing and commercializing innovative vaccines to prevent serious infectious diseases
    .

    The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to meet pressing global health needs
    .

    The company's COVID-19 vaccine, NVX-CoV2373, has received conditional authorization from multiple regulatory agencies around the world, including the European Commission and the World Health Organization
    .

    The vaccine is also under scrutiny from multiple regulatory agencies around the world
    .

    In addition to the COVID-19 vaccine, Novavax is currently evaluating a COVID seasonal influenza combination vaccine, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza research candidate, in a Phase 1/2 clinical trial
    .

    These vaccine candidates incorporate Novavax's proprietary saponin-based Matrix-M™ adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies
    .

    Novavax said it expects to start a larger Phase 2 trial by the end of this year, and a vaccine could be ready to roll out by the end of 2023
    .

    References: 1.
    https://——List of recent popular activities——▼On April 25, AAV gene therapy product and process quality control strategy▼4 April 27, Agilent Cell and Gene Therapy Webinar Series▼ April 28, Focus on mRNA Industrialization: Key Considerations for Raw Materials and Purification Processes
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.